TLDR
- AbbVie slides 6.5% as strong revenue fails to calm outlook reaction
- AbbVie stock sinks despite growth and bold 2026 expansion plans
- AbbVie drops sharply even as immunology and pipeline surge
- Strong results, weak reaction: AbbVie tumbles after guidance
- AbbVie falls near lows after earnings despite portfolio growth
AbbVie (ABBV) shares fell sharply to $210.89, down 6.52%, as heavy selling pressure offset strong revenue gains and its new 2026 outlook. The stock moved near session lows after early stability faded, and the decline followed its latest financial update. ABBV continued highlighting broad portfolio growth while preparing for another expansion cycle in 2026.
Full-Year Results Show Broad Revenue Strength for ABBV
ABBV reported full-year net revenues of $61.16 billion, and performance increased 8.6 percent on a reported basis. The company also posted adjusted diluted EPS of $10.00, and results reflected acquisition-related expenses. ABBV showed strong momentum across immunology, neuroscience and oncology despite mixed movements in legacy products.
The immunology portfolio recorded $30.406 billion in global revenue, and Skyrizi remained the top contributor. Rinvoq also expanded its position in multiple indications while Humira continued its expected decline. Even so, ABBV used its diversified mix to stabilize performance across several therapeutic areas.
Neuroscience delivered $10.767 billion in revenue, and newer products supported double-digit growth. Botox Therapeutic and Vraylar advanced their global reach with expanding clinical use. ABBV also highlighted progress in migraine treatments as Ubrelvy and Qulipta grew their combined base.
Fourth-Quarter Performance Supports ABBV’s Expansion Plans
Fourth-quarter revenue reached $16.618 billion, and ABBV recorded 10% reported growth. Immunology again led the gains with Skyrizi and Rinvoq delivering strong demand across key markets. However, Humira continued its lower contribution as biosimilar competition increased.
Neuroscience reported $2.961 billion in quarterly revenue, and multiple products advanced across approved indications. Stronger results in migraine and psychiatric care added more balance to the portfolio. ABBV maintained steady operating performance while controlling core expenses.
Oncology generated $1.664 billion in quarterly revenue, and performance remained mixed across key brands. Imbruvica declined as competition widened while Venclexta and Elahere posted higher revenue. ABBV continued focusing on new oncology combinations to strengthen long-term growth.
Pipeline Progress and 2026 Guidance Reinforce ABBV’s Strategic Direction
ABBV advanced several programs, and the company secured multiple regulatory submissions across major markets. New indications for Rinvoq and Aquipta showed progress, and expanded oncology data supported future evaluations. ABBV completed an agreement to acquire a device facility to enhance production capacity.
Recent approvals supported pipeline expansion, and Epkinly advanced into broader lymphatic indications. ABBV also signed a new licensing deal for RC148 as it widened its oncology assets. The company continued pursuing combination studies to strengthen future positioning.
ABBV issued 2026 adjusted EPS guidance of $14.37 to $14.57, and expectations excluded acquisition-related charges. The company emphasized continued revenue growth across its major portfolios. ABBV positioned itself for sustained momentum as new treatments and expanded manufacturing support its next phase.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
